GlassScriptPhysician profile
Hy V Phan
NPI 1144373408
$5,869.39
in general payments reported to CMS, 2019-2025
20 companies · $678 in 2025
The $678 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $556 · 2021: $721 · 2022: $931 · 2023: $1,126 · 2024: $1,099 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.66 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $785.41 | 2019-2025 | Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $637.88 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $626.43 | 2020-2025 | Caplyta |
| Alkermes, INC. | $555.99 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $551.10 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $505.04 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $467.15 | 2019-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $399.49 | 2019-2024 | Fanapt, Hetlioz |
| Indivior INC. | $324.52 | 2019-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $279.14 | 2019-2022 | |
| Lundbeck LLC | $214.44 | 2019-2025 | Rexulti |
| Allergan, INC. | $172.07 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $83.11 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $82.49 | 2021-2024 | Trintellix |
| Tempus Ai, INC | $59.89 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $43.07 | 2021 | |
| Merck Sharp & Dohme LLC | $32.10 | 2019-2021 | |
| Axsome Therapeutics, INC. | $22.71 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $14.47 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.89 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hy Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.